Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$13.06 USD

13.06
98,026

-0.28 (-2.10%)

Updated May 16, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FDA Okays Label Expansion of Pacira's Exparel's, Stock Up

by Zacks Equity Research

Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.

    Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why

    by Zacks Equity Research

    Let us look at the factors that have led to the increase in share price of Emergent (EBS).

      Novo Nordisk Obtains Licence for Sickle Cell Disease Program

      by Zacks Equity Research

      Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

        Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session

        by Zacks Equity Research

        Shares of Rigel Pharmaceuticals (RIGL) rose over 8% yesterday.

          Bio-Path Leukemia Combo Study Shows Positive Early Data

          by Zacks Equity Research

          Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

            Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU

            by Zacks Equity Research

            Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.

              Alkermes Sinks as FDA Refuses Depression Drug Review

              by Zacks Equity Research

              Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was developed for major depressive disorder (MDD).

                Edge Therapeutics Loses Edge on Failure of Late-Stage Study

                by Zacks Equity Research

                Edge Therapeutics (EDGE) plummeted significantly after the company announced discontinuation of the pivotal late stage study on lead candidate.

                  Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?

                  by Zacks Equity Research

                  Valeant's (VRX) stock has lost roughly 21% of its value in 2018 despite management's efforts for a turnaround after the turmoil in 2016.

                    Novo Nordisk Poised on Strong Pipeline Amid Competition

                    by Zacks Equity Research

                    Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.

                      Alexion (ALXN) Gains On Positive Date From Lead Candidate

                      by Zacks Equity Research

                      Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.

                        ArQule (ARQL) in Focus: Stock Moves 15.6% Higher

                        by Zacks Equity Research

                        Shares of ArQule (ARQL) rose nearly 16% yesterday.

                          Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress

                          by Zacks Equity Research

                          Catalyst Pharma (CPRX) reports in-line fourth-quarter 2017 loss and is on track to resubmit its new drug application for Firdapse in the first quarter of 2018.

                            Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y

                            by Zacks Equity Research

                            Arena (ARNA) reports narrower-than-expected Q4 loss. However, revenues decrease year over year. The company is likely to advance ralinepag in phase III study in the second half of 2018.

                              Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4

                              by Zacks Equity Research

                              Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2017.

                                Aradigm Files MAA for Bronchiectasis Candidate in the EU

                                by Zacks Equity Research

                                Aradigm (ARDM) submits regulatory applications for its bronchiectasis candidate, Linhaliq, in the EU. A response from the EMA is awaited within 21 days to notify if the filing is complete.

                                  Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump

                                  by Zacks Equity Research

                                  It seems to be a wise decision for investors to drop Portola Pharmaceuticals (PTLA) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.

                                    Pfizer Gets FDA Panel Backing for New Indication for Xeljanz

                                    by Zacks Equity Research

                                    Pfizer's (PFE) Xeljanz received a unanimous vote from an FDA advisory committee to include the ulcerative colitis (UC) indication in its label .

                                      Corcept Plans Korlym Label Expansion, Pipeline in Progress

                                      by Zacks Equity Research

                                      Corcept (CORT) is currently working on developing Korlym for additional indications. It also remains focused at the development of its pipeline progress.

                                        Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing

                                        by Zacks Equity Research

                                        Bristol-Myers (BMY) Opdivo becomes the first and only FDA-approved PD-1 inhibitor for every four-week dosing.

                                          Lilly, Boehringer to Expand Jardiance Heart Failure Program

                                          by Zacks Equity Research

                                          Lilly (LLY) and Boehringer plan to expand their clinical trial program for Jardiance in chronic heart failure through clinical trials.

                                            Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink

                                            by Zacks Equity Research

                                            Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.

                                              Pacira (PCRX) Posts Earnings in Q4, Revenues in Line

                                              by Zacks Equity Research

                                              Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.

                                                Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress

                                                by Zacks Equity Research

                                                Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.

                                                  Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y

                                                  by Zacks Equity Research

                                                  Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The top line however, drops year over year.